Last reviewed · How we verify
MBX 2109
At a glance
| Generic name | MBX 2109 |
|---|---|
| Also known as | Canvuparatide |
| Sponsor | MBX Biosciences |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism (PHASE2)
- Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function (PHASE1)
- Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism (PHASE2)
- Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MBX 2109 CI brief — competitive landscape report
- MBX 2109 updates RSS · CI watch RSS
- MBX Biosciences portfolio CI